Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

  • Alessandra Fabi
    Oncologia Medica 1, Istituto Nazionale Tumori ‘Regina Elena’, Roma, 00144, Italy
  • Diana Giannarelli
    Unità di Biostatistica, Istituto Nazionale Tumori ‘Regina Elena’, Roma, 00144, Italy
  • Luca Moscetti
    Oncologia Medica, Ospedale Modena, Modena, 41125, Italy
  • Daniele Santini
    Oncologia Medica, Campus Bio-medico Universitario, Roma, 00128, Italy
  • Alberto Zambelli
    Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo, 24127, Italy
  • Michelino De Laurentiis
    Breast Unit, Istituto Pascale, Napoli, 80131, Italy
  • Michele Caruso
    Humanitas Centro Catanese di Oncologia, Catania, 95126, Italy
  • Daniele Generali
    Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi di Trieste, 34127, Trieste, Italy
  • Enrichetta Valle
    Oncologia Medica, Ospedale Businco, Cagliari, 09121, Italy
  • Vita Leonardi
    Oncologia Medica, ARNAS Civico, Palermo, 90127 Italy
  • Katia Cannita
    Oncologia Medica Ospedale L'Aquila, L'Aquila, 67100, Italy
  • Grazia Arpino
    Oncologia Medica, Università Federico II, Napoli, 80138, Italy
  • Gianfranco Filippelli
    Oncologia PO di Paola, ASP di Cosenza, Cosenza, Italy
  • Gianluigi Ferretti
    Oncologia Medica 1, Istituto Nazionale Tumori ‘Regina Elena’, Roma, 00144, Italy
  • Marianna Giampaglia
    Oncologia Medica, Ospedale San Carlo, Potenza, 85100, Italy
  • Filippo Montemurro
    Investigative Clinical Oncology, Candiolo Cancer Institute-FPO, IRCCS, 10060 Candiolo, Torino, Italy
  • Cecilia Nisticò
    Oncologia Medica 1, Istituto Nazionale Tumori ‘Regina Elena’, Roma, 00144, Italy
  • Simona Gasparro
    Oncologia Medica 1, Istituto Nazionale Tumori ‘Regina Elena’, Roma, 00144, Italy
  • Francesco Cognetti
    Oncologia Medica 1, Istituto Nazionale Tumori ‘Regina Elena’, Roma, 00144, Italy

抄録

<jats:p> Aim: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen. Patients & methods: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73). Results: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14–3.58; p = 0.01). Conclusion: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting. </jats:p>

収録刊行物

  • Future Oncology

    Future Oncology 13 (30), 2791-2797, 2017-12

    Future Medicine Ltd

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ